Table 1.
The COVID-19 progression, the intensity of anti-NP response, and liver injury after acute SARS-CoV-2 infection in patients with or without chronic hepatitis B.
| All patients (n = 67) | COVID-19 patients with HBsAg positive (n = 7) | COVID-19 patients without HBV (n = 60) | p-value | |
|---|---|---|---|---|
| HBsAg positive | 7 (10.4) | 7 (100.0) | 0 | – |
| HBeAg positive | 0 | 0 | 0 | – |
| Comorbidity besides Hepatitis B | 21/67 (31.3) | 2/7 (28.6) | 19/60 (31.7) | >0.999 |
| Pulmonary disease † | 3 (4.5) | 1 (14.3) | 2 (3.3) | |
| Diabetes and/or Hypertension | 15 (22.3) | 1 (14.3) | 14 (23.3) | |
| Hyperlipemia and/or CHD | 3 (4.5) | 0 | 3 (5.0) | |
| Liver injury at admission # | 5/67 (7.5) | 0 | 5/60 (8.3) | >0.999 |
| Liver injury admission & during hospitalization | 19/67 (28.4) | 3/7 (42.9) | 16/60 (26.7) | 0.395 |
| Liver injury type # | 0.432 | |||
| Hepatocellular | 3/67 (4.5) | 1/7 (14.3) | 2/60 (3.3) | |
| Ductular | 11/67 (16.4) | 2/7 (28.6) | 9/60 (15.0) | |
| Mix | 5/67 (7.5) | 0 | 5/60 (8.3) | |
| COVID-19 progression after admission | 14/67 (20.9) | 2/7 (28.6) | 12/60 (20.0) | 0.63 |
| COVID-19 stable after admission | 53/67 (79.1) | 5/7 (71.4) | 48/60 (80.0) | 0.63 |
| Shedding time of SARS-CoV-2, days* | 25.0 ± 9.4 | 27.1 ± 9.0 | 24.7 ± 9.5 | 0.52 |
| anti-NP-IgM development | 28/58 (48.3) | 4/7 (57.1) | 24/51 (47.1) | 0.701 |
| weak-response | 10/58 (17.2) | 1/7 (14.3) | 9/51 (17.6) | >0.999 |
| strong-response | 18/58 (31.0) | 3/7 (42.9) | 15/51 (29.4) | 0.665 |
| Days of anti-NP-IgM first detectable § | 12.3 ± 4.4 | 12.5 ± 3.7 | 12.2 ± 4.6 | 0.909 |
| anti-NP-IgG development | 45/54 (83.3) | 6/7 (85.7) | 39/47 (83.0) | >0.999 |
| weak-response | 33/54 (61.1) | 4/7 (57.1) | 29/47 (61.7) | >0.999 |
| strong-response | 12/54 (22.2) | 2/7 (28.6) | 10/47 (21.3) | 0.645 |
| Days of anti-NP-IgG first detectable § | 14.3 ± 4.9 | 15.8 ± 6.2 | 14.0 ± 4.7 | 0.405 |
| Duration of Hospitalization, days | 21.0 ± 9.1 | 25.0 ± 10.7 | 20.6 ± 8.9 | 0.228 |
| COVID-19 course, days | 27.6 ± 9.2 | 32.0 ± 10.4 | 27.0 ± 9.0 | 0.178 |
| Discharge | 67/67 (100.0) | 7/7 (100.0) | 60/60 (100.0) | >0.999 |
† Includes one patient with bronchiectasis and chronic bronchitis, one patient with pulmonary tuberculosis, and one patient with asthma. CHD, coronary heart disease. # In this study, we defined ALT and/or AST more than 3 times of the upper limit units (ULN), GGT, and/or TBIL more than 2 × ULN as liver injury. ALT and/or AST over 3 × ULN were classified as hepatocellular type, GGT and/or TBIL over 2 × ULN as ductular type, while combined with ALT and/or AST over 3 × ULN and GGT and/or TBIL over 2 × ULN as mix type. * Virus shedding in any type of sample, including nasopharyngeal swab, sputum, and stool. § Days from symptom onset. Data are mean ± standard deviation or n/N (%), where N is the total number of patients with available data.